Filtered By:
Condition: Thrombosis
Drug: Cilostazol

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis
CONCLUSIONS: High PP during the acute phase of ischemic stroke appears to be associated with ischemic stroke recurrence and neurological deterioration, particularly if PP is elevated both on admission and 24 h later after admission.PMID:37081614 | DOI:10.5551/jat.64079
Source: Journal of Atherosclerosis and Thrombosis - April 20, 2023 Category: Cardiology Authors: Tadashi Ozawa Shigeru Fujimoto Junya Aoki Kosuke Matsuzono Kazumi Kimura Source Type: research

Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com
CONCLUSIONS: Long-term DAPT using cilostazol reduced the recurrence of ischemic stroke and prolonged the recurrence-free time in male patients, but not in female patients.PMID:36070920 | DOI:10.5551/jat.63660
Source: Journal of Atherosclerosis and Thrombosis - September 7, 2022 Category: Cardiology Authors: Haruhiko Hoshino Kazunori Toyoda Katsuhiro Omae Kaito Takahashi Shinichiro Uchiyama Kazumi Kimura Keiji Yamaguchi Kazuo Minematsu Hideki Origasa Takenori Yamaguchi CSPS.com Trial Investigators Source Type: research

Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
CONCLUSIONS: The evidence identified indicates that NOACs compared with standard-dose VKAs may increase the risk of stroke and do not appear to alter the risk of other outcomes (moderate-certainty evidence). Using high-dose VKA versus standard-dose VKA did not alter the risk of any thromboembolic event or major bleeding but may increase the risk of any form of bleeding (low-certainty evidence). Standard-dose VKA combined with an AP agent compared with standard-dose VKA alone may increase the risk of any thromboembolic event and does not appear to alter the risk of major bleeding or other outcomes (low-certainty evidence). ...
Source: Cochrane Database of Systematic Reviews - October 12, 2020 Category: General Medicine Authors: Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A Tags: Cochrane Database Syst Rev Source Type: research

Tachycardia Changes Increase Neurological Deterioration in Patients with Acute Non-Cardioembolic Stroke: An ADS Post-Hoc Analysis
CONCLUSIONS: Tachycardia changes increase neurological deterioration even in patients with non-cardioembolic acute stroke. DAPT consisting of aspirin and cilostazol increases the proportion of tachycardia changes and is not superior to aspirin monotherapy.PMID:35283411 | DOI:10.5551/jat.63409
Source: Journal of Atherosclerosis and Thrombosis - March 14, 2022 Category: Cardiology Authors: Kosuke Matsuzono Shigeru Fujimoto Junya Aoki Tadashi Ozawa Kazumi Kimura ADS Investigators Source Type: research

Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation
CONCLUSIONS: Cilostazol-based dual antiplatelet therapy could be recommended as an effective and safe therapy regimen among patients undergoing intracranial or extracranial artery stent implantation.PMID:36328566 | DOI:10.5551/jat.63632
Source: Journal of Atherosclerosis and Thrombosis - November 3, 2022 Category: Cardiology Authors: Hui Liu Tengfei Shao Tao Yang Di Li Huan Wang Yue Cheng Tingzheng Zhang Jinping Zhang Source Type: research